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ABSTRACT 37 
Objective:  38 
To define risk thresholds for cost-effectiveness of risk-reducing salpingo-39 
oophorectomy(RRSO) for ovarian cancer(OC) prevention in low/intermediate risk 40 
postmenopausal women. 41 
Methods 42 
A decision-analytic model compares lifetime costs-&-effects of offering ‘RRSO’ with ‘no 43 
RRSO’ to postmenopausal women ≥50years for different lifetime OC-risk thresholds: 2%, 44 
4%, 5%, 6%, 8% and 10%. Well established data from the literature are used to estimate total 45 
costs, effects in terms of Quality-Adjusted-Life-Years(QALYs), cancer incidence, 46 
incremental cost-effectiveness ratio(ICER) and impact. Costs are reported at 2012 prices; 47 
costs/outcomes discounted at 3.5%. Deterministic/Probabilistic sensitivity analysis(PSA) 48 
evaluate model uncertainty. 49 
Results  50 
RRSO does not save QALYs and is not cost-effective at the 2% general population lifetime 51 
OC-risk.  At 4% OC-risk RRSO saves QALYs but is not cost-effective. At risk thresholds 52 
≥5%, RRSO saves more life-years and QALYs and is highly cost-effective. The ICERs for 53 
OC-risk levels 5%, 6%, 8% and 10% are £15247, £9958, £4584, and £1864 respectively. The 54 
gain in life-years from RRSO equates to 29.2, 40.1, 62.1 and 80.3 days at risk thresholds of 55 
5%, 6%, 8% and 10% respectively. The results are not sensitive to treatment costs of 56 
RRSO/OC/cardiovascular events but are sensitive to utility-scores for RRSO. On PSA, 67%, 57 
80%, 84%, 91% and 94% of simulations at risk thresholds of 4%, 5%, 6%, 8% and 10% 58 
respectively are cost-effective for RRSO. 59 
Conclusion 60 
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RRSO is highly cost-effective in postmenopausal women aged >50 with ≥5% lifetime OC-61 
risk and increases life-expectancy by >29.2days. The results could have significant clinical 62 
implications given the improvements in risk prediction and falling costs of genotyping. 63 
 64 
   65 
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INTRODUCTION 66 
There are 239,000 new cases and 152,000 deaths from ovarian cancer (OC) worldwide 67 
annually.[1] Advances in treatment have led to only small improvements in survival over the 68 
last 10-20 years, and it remains the commonest cause of deaths from gynaecological 69 
cancer.[2] Screening for OC has not yet been shown to reduce mortality,[3] and the most 70 
effective risk-reducing procedure currently available is surgical removal of both tubes and 71 
ovaries. Risk reducing salpingo-oophorectomy (RRSO) has been found to have a hazard ratio 72 
(HR) being 0.06 (CI:0.02,0.17) in a low-risk population[4] and 0.21 (CI:0.12,0.39) in 73 
BRCA1/BRCA2 carriers.[5] However, currently it is only routinely available to women from 74 
high-risk families, such as those carrying high penetrance BRCA1/BRCA2 and mismatch-75 
repair gene mutations (lifetime OC risk ≥10%), for whom the cost-effectiveness[6] of such an 76 
approach is well established. 77 
 78 
In the general (low-risk) population, the OC risk distribution includes women with both 79 
higher (but <10%) and lower than the average lifetime risk estimates (1.3%-2%).[2, 7]. A 80 
number of lifestyle, reproductive and medical factors such as contraceptive pill use, tubal 81 
ligation, parity, endometriosis, subfertility, age and family-history have been shown to be 82 
associated with OC risk. In addition 17 common genetic variants influencing OC risk have 83 
been identified through genome wide association studies (GWAS) and other large-scale 84 
genotyping efforts.[8] Although the risk with each individual variant is small, women who 85 
carry multiple risk alleles have a 2-3 fold higher risk estimate than those with a low polygenic 86 
load.[9, 10] RRSO has not been formally evaluated as a risk reducing option in these lower 87 
risk populations and the ‘risk threshold’ at which this intervention may become cost-effective 88 
for prevention of sporadic OC has not been defined.  As the median age of diagnosis of 89 
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sporadic OC is >65 years,[11] RRSO could be restricted to postmenopausal women >50 90 
years age.  91 
 92 
We hypothesise that in postmenopausal women >50 years age, RRSO may become cost-93 
effective for prevention of sporadic OC at <10% lifetime risk thresholds. We use well 94 
established data from the literature to describe a decision analysis model comparing ‘RRSO’ 95 
with ‘no RRSO’ at different OC risk thresholds. Defining the risk thresholds and 96 
circumstances in which RRSO can be offered to lower risk postmenopausal women on a 97 
population basis for OC prevention is an important step towards the implementation of 98 
predictive, preventive, personalized, and participatory (P4) medicine. The results have 99 
immediate implications as currently postmenopausal women in the general population cannot 100 
access primary risk reducing salpingo-oophorectomy for OC prevention.  101 
 102 
METHODS 103 
A decision-analytic model (Figure-1) was developed to compare the lifetime costs and effects 104 
of offering RRSO to women aged 51years for different risk thresholds of developing OC. The 105 
model was programmed in Microsoft Excel, and run for the OC risk thresholds: 2%, 4%, 5%, 106 
6%, 8% and 10%. As this analysis concerns prevention of OC not linked to high penetrance 107 
genes, the median age of diagnosis of sporadic OC is >65 years and 83% of all OC occurs in 108 
women >50 years, we restrict the analysis to post-menopausal women ≥51 years age. OC 109 
screening has not been shown to save lives and is not routinely offered in clinical practice. 110 
Hence, it is not included in the model.  111 
 112 
Figure-1 reflects outcomes based on a decision to perform RRSO or not. Each decision point 113 
in the model is called a ‘node’ and each path extending from a node is called a decision 114 
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‘branch’. Each branch represents a mutually exclusive course/outcome. Each decision is 115 
given a probability and values for each outcome are calculated. We assume that the risk 116 
threshold for the woman has already been identified through existing risk prediction 117 
algorithms based on known risk factors and these risk prediction costs are not included. 118 
Model outcomes include OC and excess deaths from mainly cardiovascular causes.[4] 119 
 120 
In line with guidelines on the reference case for economic evaluation from the National 121 
Institute for Health and Care Excellence(NICE), all costs and outcomes were discounted at 122 
3.5%.[12] 123 
 124 
Probabilities 125 
All model pathway probabilities are detailed in Table-1. The reduction in risk from salpingo-126 
oophorectomy was taken from a population based cohort.[4] The excess death from 127 
cardiovascular mortality was taken from the Nurses Health cohort,[4] that reported 62 (361 if 128 
all deaths considered) deaths in 3056 women over 50 years with ovarian conservation 129 
compared to 123 (805 if all deaths considered) deaths in 5967 women undergoing BSO. This 130 
gives an absolute increase in risk=0.03%% (CI:-0.58%,0.65%) and numbers needed to harm 131 
(NNH)=3073 (CI:154,∞). A one-way sensitivity analysis involved rerunning the model at 132 
both lower and upper values/limits of the 95%CI or range of all probability parameters 133 
(Table-1) used in the model (Figure-2). Cancer incidence was estimated by summing the 134 
probabilities of pathways ending in OC. 135 
 136 
Costs 137 
All costs are described in Table-2 and are reported at 2012 prices. Where required they have 138 
been converted using the Hospital and Community Health Service Index.[13] In line with 139 
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NICE recommendations future healthcare costs not associated with OC were not 140 
considered.[12] 141 
 142 
Life-years 143 
Life expectancy for women who don’t develop OC was based on female life tables from 144 
Office of National Statistics.[14] Age at onset of postmenopausal OC (median=68 years) was 145 
taken from CRUK age of incidence statistics.[11] Ten year survival data (from CRUK) was 146 
used to model OC outcomes (1-year survival=72.4% (CI:72.4,72.5); 5-year survival 147 
rate=46.2% (CI:45.9,46.4); 10-year survival=34.5% (CI:33.8,35.3)).[15] After ten years 148 
survival, the probability of death was assumed to be same as the general population.  149 
 150 
Quality adjusted life years (QALYs) 151 
QALY is a measurement which expresses changes in length-of-life, while simultaneously 152 
incorporating reductions in quality-of-life. It is calculated using quality-of-life adjustment or 153 
utility-weights for each health state in the model. ‘Utility-weights’ are an indication of an 154 
individual’s preference for specific health states where ‘1’=perfect health and ‘0’=death. 155 
QALY=Survival in life-years x Utility-weight. Utility-weight for RRSO=0.95(S.D=0.1) and 156 
was obtained from a recent analysis by Grann.[16] Havrilesky[17] reported detailed utility 157 
estimates related to various health states following OC treatment using visual analogue scale 158 
and time-trade-off (TTO) methods. As visual scales comparing health state preferences have 159 
inherent biases and are generally less accurate,[18] we have utilized the TTO scores. We 160 
assumed that 70% of women present with OC at advanced stages,[19, 20] with a lower 161 
utility-score for a new diagnosis=0.55(S.D=0.29), while the remainder present at early stages 162 
with a higher utility-score=0.81(S.D=0.26). The end-stage of life utility-score where OC 163 
patients did not survive the next year=0.16(S.D=0.25). Of those who survived initial 164 
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chemotherapy the chance of recurrence with early disease was 10.5% annually,[21] and with 165 
advanced disease 20.6%.[19] For women with recurrent disease the mean utility-value= 166 
0.5(range:0.4-0.61) and for women in remission the utility-value=0.83(S.D=0.25).[17]  167 
 168 
Analysis 169 
The probability of being in a branch of the decision-model was calculated by multiplying 170 
together the path probabilities. The total costs and effects in terms of life-years and QALYs 171 
were then estimated by weighting the values for each branch by the probability of being in 172 
each branch. The incremental cost-effectiveness ratio (ICER) was estimated by dividing the 173 
difference in cost by the difference in effect. ICER= (Cost A–Cost B)/(Effect A–Effect B). 174 
By comparing this ICER with the £20,000-£30,000/QALY cost-effectiveness threshold used 175 
by NICE,[22] we determined whether ‘offering RRSO’ to women above a certain risk 176 
threshold was cost-effective compared with ‘no RRSO’. To explore uncertainty in the results 177 
and robustness of the model, a one-way (deterministic) sensitivity analysis was undertaken by 178 
varying each parameter in the model and then re-running the model to assess the impact on 179 
overall results. Probabilities and utility-scores were varied according to their 95% 180 
confidence-intervals/range, where available, or by +/-10%, and costs were varied by +/-30%. 181 
In addition to the one-way sensitivity results, a probabilistic sensitivity analysis (PSA) was 182 
undertaken as recommended by NICE methods guidance.[12, 23] Any variation in model 183 
parameters/variables is likely to occur in parallel rather than independently of each other. In 184 
the PSA all variables were varied simultaneously across their distributions to further explore 185 
model uncertainty. We assigned costs a gamma distribution, probabilities a beta distribution, 186 
and utilities a log-normal distribution as suggested in the literature.[24] The results of 1000 187 
simulations were plotted on a cost-effectiveness acceptability curve showing the proportion 188 
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of simulations that indicated that the intervention was cost-effective at different willingness 189 
to pay thresholds.  190 
 191 
 192 
RESULTS 193 
The discounted and undiscounted survival (life-years), lifetime costs, and QALYs for each 194 
branch in the decision model at the different OC risk thresholds of 2%, 4%, 5%, 6%, 8% and 195 
10% are given in Table-3. Discounted results show a smaller overall gain in life-196 
years/QALYs and overall cost difference, as discounting adjusts costs and outcomes that 197 
occur in the future and the cost savings generated through prevention of future OC cases is 198 
valued less.  At the 2% baseline population OC risk level, routine RRSO does not save more 199 
QALYs and is not cost-effective.  At a 4% OC risk level, RRSO saves more QALYs but is 200 
not cost-effective at the ICER=£25,577, which is above the £20,000 NICE threshold. 201 
However, at risk thresholds of ≥5%, RRSO saves more life-years and QALYs and is highly 202 
cost-effective for the NICE threshold of £20,000/QALY. The ICERs for risk levels of 5%, 203 
6%, 8% and 10% are £15247, £9958, £4584, and £1864 respectively. The gains in life 204 
expectancy from RRSO at the risk thresholds of 5%, 6%, 8% and 10% equate to 29.2, 40.1, 205 
62.1 and 80.3 days respectively. 206 
 207 
One-way sensitivity analysis results are given in Figure-2. It suggests that the results are not 208 
that sensitive to treatment costs of RRSO, OC or cardiovascular events. Results are however 209 
sensitive to excess cardiovascular deaths at the 5% threshold but not that sensitive at the 6% 210 
and 8% thresholds. It is also very sensitive to utility-scores for RRSO. The model was not 211 
cost-effective at the lower most limit of the utility-score for RRSO.  The impact of different 212 
variables on cost-effectiveness decreases as the OC risk threshold increases.  213 
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 214 
The PSA results (Figure-3) shows that at a £20,000 willingness to pay threshold/QALY, 215 
67%, 80%, 84%, 91% and 94% of simulations at risk thresholds of 4%, 5%, 6%, 8% and 216 
10%, respectively are cost-effective for RRSO. If the willingness to pay threshold is 217 
increased to £30,000/QALY, then 77%, 84%, 85%, 92% and 94% simulations are cost 218 
effective for RRSO at the above risk thresholds, respectively. 219 
 220 
DISCUSSION 221 
This is the first analysis that we are aware of that defines precise risk thresholds at which 222 
RRSO can be cost-effective for OC prevention on a population basis. Our modelling suggests 223 
that in postmenopausal women with lifetime OC risk thresholds of ≥5%, RRSO is highly 224 
cost-effective for the NICE threshold of £20,000/QALY[22] and equates to gains in life 225 
expectancy of >29.2 days.  This gain in life-years (range 29.2 to 80.3 days) compares 226 
favourably with the gain in life-years from cervical cancer screening which is reported to 227 
range between 11.6-32.4 days.[25] Our findings have significant implications for clinical 228 
practice given the falling cost of genotyping and increasing ability to better calculate an 229 
individual’s OC risk. Availability of such an approach could impact on risk management 230 
choices of ‘low/intermediate risk’ (lifetime risk <10%) women especially given the lack of an 231 
effective screening strategy for OC. If widely adopted it has the potential to contribute to 232 
reducing the OC burden in the population.  233 
 234 
Restricting use to women >50 years enables primary surgical prevention to be offered with 235 
less side effects. The increased all-cause mortality associated with bilateral oophorectomy 236 
reported by the Nurses Health[4] and Olmsted County[26] studies were predominantly in 237 
women <45[26]-50[4] years who did not take hormone replacement therapy. The same is true 238 
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for cardiovascular, bone and neurological risks.[4, 26, 27] Most sporadic OC (not related to 239 
BRCA/mismatch repair gene mutations) occurs at >50 years, with the median age of 240 
diagnosis being >65 years[11]. Although precise data on the proportion of OC <50 years in 241 
BRCA1/BRCA2/MMR-negative individuals who have a life time OC risk ≥5% risk are not 242 
currently available, this risk under 50 is likely to be minimal. 243 
In our analysis, the lifetime OC risk threshold for RRSO in postmenopausal women was 244 
≥5%. This 5% risk threshold is significantly lower than the OC risk (18-40%) in 245 
BRCA1/BRCA2 carriers,[28] and also less than the risk of OC in Lynch Syndrome women 246 
(6-14%).[29] OC risk prediction is increasingly possible and general population models based 247 
on known epidemiological risk and protective factors have recently been published.[30, 31] 248 
Recently we quantified the population distribution of lifetime risks of OC by adding common 249 
genetic (SNP) risk factors to the known epidemiologic (contraceptive use, parity, tubal 250 
ligation, endometriosis, first degree relative with OC) factors.[10] Eight combinations of risk 251 
factors gave a life time OC risk ≥5% and 2% of the US population would have a lifetime risk 252 
≥5%.[10] RRSO could be of benefit to all such women. Newer OC SNPs are constantly being 253 
identified through large consortia led collaborative work, incorporation of which will further 254 
improve performance of such models. Alongside such progress, major advancements in 255 
genetic testing technology and falling costs now enables individual SNP information to be 256 
made available at a low cost.  Additionally, other lifestyle factors including aspirin and 257 
menopausal HRT use are being identified through pooled analyses.  As models get more 258 
sophisticated incorporating additional genetic and epidemiologic data, their ability to predict 259 
ovarian cancer risk will improve and their applicability will rise. 260 
 261 
Our analysis has several strengths. It incorporates impact on OC risk and fulfils various 262 
requirements suggested by NICE for health-economic decision making. We use current 263 
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practice as a comparator, QALYs to measure health-outcomes, a 3.5% discount rate on costs 264 
and health outcomes and, well established population-based data for parameters in the 265 
analysis.[12] Our model includes potential excess deaths from coronary events in the 266 
postmenopausal population as reported in the most recent analysis of the Nurses Health 267 
Study.[4] This is despite no such adverse association being reported from the Women’s 268 
Health Initiative cohort.[32] We have also included the potential reduction in QALYs 269 
following RRSO. The ‘time-horizon’ in our analysis is long enough to reflect important 270 
differences in costs and outcomes.[12] In order to minimize over-estimating benefits of 271 
RRSO, we have been conservative in our use of costs for OC diagnosis and treatment, by 272 
including a minimal subset of baseline costs. We have not included all costs for additional 273 
investigations, treatment of recurrence or management of complications. Inclusion of these 274 
additional costs would further increase cost-effectiveness of the model at a given risk 275 
threshold. We have also not included costs of genetic testing in the analysis and this may be a 276 
constraint. We have not included the excess mortality due to lung/colorectal cancer reported 277 
in the Nurses Health Study. However, this excess cancer mortality may be confounded by 278 
cigarette smoking or other risk related behaviours. Smoking itself is associated with early 279 
menopause.[33, 34] Data from the 185,017 women NIH-AARP (American Association of 280 
Retired Persons) Diet-&-Health Study found that when stratified by smoking status, the 281 
increased lung cancer risk associated with bilateral oophorectomy was restricted to smokers, 282 
and absent in non-smokers.[33] Additionally, data from 337,802 women in the European 283 
Prospective Investigation into Cancer and Nutrition (EPIC) study found no significant 284 
association between age at menarche/menopause or type of menopause (surgical/natural) and 285 
colorectal cancer risk.[35] We have not accounted for complications related to RRSO. A 1.5-286 
5% complication rate has been reported in high risk women.[36, 37] It is important that this 287 
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issue be discussed by the treating clinician at time of consent and be built into the decision 288 
making process of whether to undergo surgery or not.  289 
 290 
The deterministic sensitivity analysis permitted scrutiny of model outcomes and identification 291 
of variables exerting most influence. The 95% confidence-limits for probabilities explored in 292 
our sensitivity analysis were quite wide, adding to the strength of the results. The lack of 293 
statistically significant effect on outcome despite 30% variation in costs indicates that costs 294 
of RRSO, OC or cardiovascular treatment, are less important in influencing overall results. 295 
That the model remains largely cost-effective despite probabilities varying widely is 296 
reassuring. The reduction in level of impact exerted by different variables at increasing OC 297 
risk thresholds is expected and reassuring. It is interesting that the model is highly sensitive to 298 
the lower limit of the utility-score for RRSO at all risk levels. This is probably because the 299 
standard deviation is large. Hence, there is need for further research on RRSO utility-scores 300 
to better understand and improve the precision of its estimate. Of note nearly all published 301 
work is on the pre-menopausal population where the impact on quality-of-life is different. 302 
Separate utility-scores need to be developed for pre and postmenopausal RRSO.  303 
 304 
The PSA undertaken is recommended by decision making bodies and adds to the robustness 305 
of our results.[12] It permits simultaneous variation in probabilities of all parameters to fully 306 
characterise model uncertainties and its effect on overall results. That 80-94% of simulations 307 
on PSA were cost-effective for the risk thresholds ≥5% reconfirms the health-economic 308 
benefit of RRSO at these risk levels for OC prevention. 309 
 310 
Health economic assessments are crucial for determining the appropriateness of resource 311 
allocation for cost intensive population-based interventions. Rising health care costs and ever 312 
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increasing price of new OC treatments/drug therapies in a challenging economic environment 313 
further magnify the importance of newer cost-effective preventive strategies. Our findings 314 
thus have potentially important implications for clinical practice especially for the individual 315 
woman and for reducing the burden of OC. A key next step would be assessment of the 316 
acceptability of such a surgical intervention to decrease risk in postmenopausal women aged 317 
over 50 with lifetime OC risk of >5-<10%. The increasing availability of panel testing, 318 
identification newer moderate penetrance genes and common genetic variants and improved 319 
risk prediction models has made it possible to identify a number of women who can fall into 320 
this risk category. Tools/decision aids to facilitate understanding of risk and informed consent 321 
would need to be developed. Implementation of such an approach will necessitate 322 
information dissemination for raising health professional/public awareness and education.  323 
All these will have an added cost. Close attention will also need to be paid to developing well 324 
defined care and patient referral pathways in co-ordination with general practitioners, 325 
geneticists, gynaecologists and commissioners of care, as well as implementation studies for 326 
collecting long term outcomes.  327 
 328 
 329 
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FIGURE LEGENDS 357 
Figure-1: Decision Model Structure  358 
The upper part of the model structure reflects ‘no RRSO’ for a given OC risk threshold. The 359 
lower part of the model depicts the option of RRSO for the same OC risk threshold. This 360 
model is run at each of the different thresholds for OC risk (2%, 4%, 5%, 6%, 8% and 361 
10%).Each decision point in the model is a ‘node’ and each path extending from a node is a 362 
decision ‘branch’. Each branch represents a mutually exclusive course or outcome. Each 363 
decision is given a probability (probabilities used in the model are detailed in Table1) 364 
highlighted in a white box along the decision branch. Values for each outcome are calculated. 365 
Cancer incidence is estimated by summing the probabilities of pathways ending in ovarian 366 
cancer. Final outcomes (blue boxes on the right of the figure) of each path include 367 
development of OC, no OC and excess deaths mainly from heart disease (Branch E).   368 
OC-Ovarian Cancer; No OC - No Ovarian Cancer developed, RRSO –Risk reducing 369 
salpingo-oophorectomy 370 
 371 
Figure 2: One way Deterministic Sensitivity Analyses  372 
One-way sensitivity analysis (at the 8%, 6%, 5% risk thresholds) for all probabilities, costs 373 
and utilities in terms of ICER of RRSO compared to No RRSO at the different ovarian cancer 374 
risk thresholds. Y-axis: Incremental cost-effectiveness ratio (ICER): Cost (£) per quality 375 
adjusted life year (QALY) (discounted). X-axis: Probability, cost and utility parameters in the 376 
model. The model is run at both lower and upper values/limits of the 95% confidence interval 377 
or range of all probability parameters described in Table-1/methods; and both lower and 378 
upper values/limits of the cost and utility-score parameters given in Table 2. Costs are varied 379 
by +/- 30%. Maximum value’ represents outcomes for upper limit and ‘Minimum value’ 380 
represents outcomes for lower limit of the parameter.  381 
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OC- Ovarian cancer, RRSO –Risk reducing salpingo-oophorectomy 382 
 383 
Figure-3: Probabilistic Sensitivity Analysis  384 
Shows the Cost-effectiveness acceptability curve (for different OC risk thresholds) in which 385 
all model parameters/variables are varied simultaneously across their distributions to further 386 
explore model uncertainty.  X-axis: Incremental cost-effectiveness ratio (ICER) in terms of 387 
Cost (£s)/QALY; Y-axis: Proportion of simulations. The results of 1000 simulations were 388 
plotted on a cost-effectiveness acceptability curve showing the proportion of simulations (Y-389 
axis) that indicated that the intervention was cost-effective at different willingness to pay 390 
thresholds (X-axis). The solid red line marks the proportion of simulations found to be cost-391 
effective at the £20,000 threshold used by NICE. 67-94% simulations are cost effective in 392 
this analysis. 393 
 394 
OC- Ovarian cancer, RRSO- Risk reducing salpingo-oophorectomy 395 
 396 
 397 
  398 
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FIGURE-1 Decision Model Structure 399 
 400 
 401 
 402 
 403 
 404 
Figure-1: Decision Model Structure.  405 
The upper part of the model structure reflects ‘no RRSO’ for a given OC risk threshold. The lower 406 
part of the model depicts the option of RRSO for the same OC risk threshold. This model is run at 407 
each of the different thresholds for OC risk (2%, 4%, 5%, 6%, 8% and 10%).Each decision point in the 408 
model is a ‘node’ and each path extending from a node is a decision ‘branch’. Each branch 409 
represents a mutually exclusive course or outcome. Each decision is given a probability (probabilities 410 
used in the model are detailed in Table1) highlighted in a white box along the decision branch. 411 
Values for each outcome are calculated. Cancer incidence is estimated by summing the probabilities 412 
of pathways ending in ovarian cancer. Final outcomes (blue boxes on the right of the figure) of each 413 
path include development of OC, no OC and excess deaths mainly from heart disease (Branch E).   414 
OC-Ovarian Cancer; No OC - No Ovarian Cancer developed, RRSO –Risk reducing salpingo-415 
oophorectomy 416 
 417 
 418 
 419 
 420 
  421 
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 422 
Figure-2 One way Deterministic Sensitivity Analyses 423 
 424 
 425 
 426 
 427 
Figure 2: Deterministic Sensitivity Analyses. One-way sensitivity analysis (at the 8%, 6%, 5% risk 428 
thresholds) for all probabilities, costs and utilities in terms of ICER of RRSO compared to No RRSO at 429 
the different ovarian cancer risk thresholds. Y-axis: Incremental cost-effectiveness ratio (ICER): Cost 430 
(£) per quality adjusted life year (QALY) (discounted). X-axis: Probability, cost and utility parameters 431 
in the model. The model is run at both lower and upper values/limits of the 95% confidence interval 432 
or range of all probability parameters described in Table-1/methods; and both lower and upper 433 
values/limits of the cost and utility-score parameters given in Table 2. Costs are varied by +/- 30%. 434 
Maximum value’ represents outcomes for upper limit and ‘Minimum value’ represents outcomes for 435 
lower limit of the parameter.  436 
OC- Ovarian cancer, RRSO –Risk reducing salpingo-oophorectomy 437 
 438 
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Figure 3: Probabilistic sensitivity analysis  440 
 441 
 442 
 443 
 444 
 445 
Figure-3: Probabilistic sensitivity analysis: Shows the Cost-effectiveness acceptability curve (for 446 
different OC risk thresholds) in which all model parameters/variables are varied simultaneously 447 
across their distributions to further explore model uncertainty.  X-axis: Incremental cost-448 
effectiveness ratio (ICER) in terms of Cost (£s)/QALY; Y-axis: Proportion of simulations. The results of 449 
1000 simulations were plotted on a cost-effectiveness acceptability curve showing the proportion of 450 
simulations (Y-axis) that indicated that the intervention was cost-effective at different willingness to 451 
pay thresholds (X-axis). The solid red line marks the proportion of simulations found to be cost-452 
effective at the £20,000 threshold used by NICE. 67-94% simulations are cost effective in this 453 
analysis. 454 
 455 
OC- Ovarian cancer, RRSO- Risk reducing salpingo-oophorectomy 456 
 457 
 458 
 459 
 460 
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TABLES 463 
 464 
Table 1: Probabilities of different pathways 465 
 466 
Probability  Value (CI) [Range] Description  Source  
P1 
0.10 
0.08 
0.06 
0.04 
0.02 
 Lifetime risk of developing ovarian cancer  Model assumption 
P2 0.94  (0.83, 0.98) Reduction in risk of ovarian cancer from RRSO Parker et al 2013[4] 
P3 0.0003 (0.0078,0) Excess risk of deaths from heart disease Parker et al 2013[4] 
CI- confidence interval, RRSO- risk reducing salpingo-oophorectomy 
Explanation: 
P1: Lifetime risk of developing ovarian cancer. The model was run over varying risk thresholds. 
P1=0.02 represents the baseline population based risk. 
P2: The reduction in ovarian cancer risk obtained from RRSO is taken from the Nurses Health 
Study, Parker et al, 2013.[4] 
P3: The absolute excess risk of deaths from heart disease = 0.03% (-0%, 0.65%). This  is taken 
from the Nurses Health Study.[4] The numbers needed to harm (NNH)= 3073 (CI 154, ∞ ). 
 467 
 468 
 469 
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Table 2: Summary of costs used in model (2012 prices)* 471 
 472 
Item Cost (£) Source 
Cost of RRSO  2,165 NHS Reference costs 
Cost of ovarian cancer diagnosis 
and initial treatment 16,044 NHS Reference costs[38], NICE guideline[39] 
Yearly cost of ovarian cancer 
treatment and follow-up: years 
1-2 
639 NHS Reference costs[38], NICE guideline[39] 
Yearly cost of ovarian cancer 
treatment  and follow-up: years 
3-5 
274 NHS Reference costs[38], NICE guideline[39] 
Terminal care cost with ovarian 
cancer 15,414 National Audit office[40] 
Cost of CHD death 3277  
*All costs were varied by +/-30% in one way sensitivity analysis 
NHS- national health service, NICE-national institutes for health and clinical excellence, , 
RRSO- risk reducing salpingo-oophorectomy,  
 Explanation 
The cost of RRSO was based on national reference costs for an upper genital tract 
laparoscopic/endoscopic intermediate procedure.[38]  
 
Costs for ovarian cancer diagnosis and treatment were derived from national reference 
costs and a recent ovarian cancer guideline developed by NICE.[38, 39] We assumed that 
the cost of diagnosis to include a pelvic examination, ultrasound scan, CA125 test, CT scan, 
percutaneous biopsy and peritoneal cytology.  
The cost of treatment included the reference cost for a lower and upper genital tract very 
complex major procedure and administration of chemotherapy based on 6 cycles of 
carboplatin and paclitaxel treatment. It was assumed that in years-1 and -2 treated 
survivors would have a further three consultant visits, a CT scan and 4 CA125 tests each 
year. In years 3 to 5 post-surgery it was assumed that survivors would have 2 consultant 
visits and 2 CA125 tests. We were conservative in our cost-estimates and did not include 
costs for additional investigations, treatment of recurrence or management of 
complications in the analysis.  
Costs for terminal care for ovarian cancer were derived from end-of-life costs for cancer 
patients based on a report from the National Audit Office, UK.[40]  
In line with NICE recommendations future healthcare costs not associated with ovarian 
cancer were not considered. 
 473 
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Table 3: Model outcomes for costs, survival (life years) and quality adjusted life years (QALYs), undiscounted and discounted 
 
 Ovarian cancer 
incidence 
Survival Discounte
d survival 
Cost Discounted 
cost 
QALY Discounted 
QALY 
10% risk         
NO RSSO 10.0% 31.376 18.518 2475 1866 31.3 18.5 
RRSO 0.6% 31.958 18.738 2314 2277 31.9 18.7 
Difference 9.4% 0.582 0.220 -161 412 0.6 0.22 
ICER      -251 1864 
8% risk        
NO RRSO 8.0% 31.501 18.565 1980 1493 31.4 18.5 
RRSO 0.5% 31.966 18.741 2285 2255 31.9 18.7 
Difference 7.5% 0.465 0.176 304 762 0.5 0.17 
ICER      605 4584 
6% risk        
NO RRSO 6.0% 31.626 18.613 1485 1119 31.6 18.58 
RRSO 0.4% 31.973 18.744 2255 2233 31.9 18.69 
Difference 5.6% 0.347 0.131 770 1113 0.4 0.11 
ICER      2116 9958 
5% risk        
NO RRSO 5.0% 31.69 18.64 1237.72 932.81 31.63 18.61 
RRSO 0.3% 31.98 18.75 2239.95 2221.31 31.92 18.69 
Difference 4.7% 0.29 0.11 1002.23 1288.49 0.29 0.08 
ICER      3409 15247 
4% risk        
NO RRSO 4.00% 31.751 18.660 990 746 31.7 18.6 
RRSO 0.24% 31.981 18.747 2225 2210 31.9 18.7 
Difference 3.76% 0.230 0.087 1235 1464 0.2 0.057 
ICER      5505 25577 
2% risk        
25 
 
NO RRSO 2.00% 31.875 18.707 495 373 31.9 18.7 
RRSO 0.12% 31.988 18.749 2195 2188 31.9 18.7 
Difference 1.88% 0.113 0.043 1700 1815 0.1 0.0 
ICER      19999 674656 
 
 
ICER- Incremental cost-effectiveness ratio, QALY- quality adjusted life year, RRSO- risk reducing salpingo-oophorectomy 
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